Musculoskeletal system

Active Implants Enters Partnership with Geistlich Pharma AG for NUsurface® Meniscus Prosthesis

Retrieved on: 
Monday, September 6, 2021

Active Implants LLC , a company that develops orthopedic implant solutions, today announced that it has reached an exclusive agreement with Geistlich Pharma AG to be the exclusive Swiss distributor of the companys NUsurface Meniscus Prothesis.

Key Points: 
  • Active Implants LLC , a company that develops orthopedic implant solutions, today announced that it has reached an exclusive agreement with Geistlich Pharma AG to be the exclusive Swiss distributor of the companys NUsurface Meniscus Prothesis.
  • The relationship between Active Implants and Geistlich Pharma began in 2019 with the launch of the MEFISTO project.
  • The NUsurface is the first artificial meniscus to be marketed in Europe and is currently under review by the U.S. Food and Drug Administration (FDA).
  • Geistlich Pharma AG is a Swiss company, owned by the family Geistlich with its headquarters in Central Switzerland in Wolhusen and in Root.

Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Retrieved on: 
Monday, August 2, 2021

BOSTON and JERUSALEM, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, today announced its poster presentation titled “A Six-month Phase 2 Study of Oral PTH in Postmenopausal Women with Low Bone Mass - An Interim Three-Month Analysis” has been selected by the Program Committee of the American Society for Bone and Mineral Research (ASBMR) for its Annual Meeting scheduled to take place on October 1-4, 2021 in San Diego, California. Dr. Arthur Santora, Entera’s Chief Medical Officer, will present the poster at both the plenary session on October 1 and the general session on October 2, as well as a special session on the Biology of the Aging Skeleton Symposium on September 30.

Key Points: 
  • Three and 6 month results, previously reported by Entera in June 2021 can be found here .
  • Osteoporosis, characterized by low bone mass and deterioration of bone tissue, can lead to decreased bone strength and increased risk of fracture.
  • The Companys most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development.
  • Entera cautions investors not to rely too heavily on the forward-looking statements Entera makes or that are made on its behalf.

Medimaps Announces Reimbursement by Center for Medicare and Medicaid Services (CMS) for Trabecular Bone Score for Osteoporosis Fracture Risk Assessment

Retrieved on: 
Thursday, July 29, 2021

This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.

Key Points: 
  • This is the first new reimbursable CPT code for fracture risk assessment in osteoporosis in almost a decade.
  • The reimbursement amount was released by CMS last week and will become effective and available January 1, 2022.
  • This is largely a result of the fact that 75% of high-risk patients are not being diagnosed timely4.
  • Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study, Journal of Bone and Mineral Research.

EQS-News: Medacta Expands Hip Revision Portfolio, Unveiling Cutting-Edge Implants for Acetabulum and Femur

Retrieved on: 
Wednesday, July 28, 2021

Medacta Expands Hip Revision Portfolio, Unveiling Cutting-Edge Implants for Acetabulum and Femur

Key Points: 
  • Medacta Expands Hip Revision Portfolio, Unveiling Cutting-Edge Implants for Acetabulum and Femur
    Medacta Expands Hip Revision Portfolio, Unveiling Cutting-Edge Implants for Acetabulum and Femur
    AMIS(R)-K Long, Iliac Screw Mpact(R) 3D Metal, and 3D Metal(R) B-Cage, after each of the items received CE marking.
  • These new products, alongside the M-Vizion(R) Modular Femoral Revision Stem, further broaden the Medacta Hip Revision Platform.
  • "By further expanding our Hip Revision Platform, we are well-positioned to meet our goal of being a uniquely valuable partner for hip surgeons worldwide.
  • The M-Vizion Femoral Modular Revision System, the core of the Medacta Hip Revision Platform, allows surgeons to feel more confident in the OR when undertaking femoral revision cases.

Miami Periodontist Implements New Treatment for TMJ Disorders

Retrieved on: 
Wednesday, July 28, 2021

MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.

Key Points: 
  • MIAMI, July 28, 2021 /PRNewswire-PRWeb/ -- Miami Periodontist and Dental Implant Specialist Dr. John Paul Gallardo has announced a new method of treating TMJ disorder using laser therapy.
  • TMJ disorders include non alignment or injury to the teeth or jaw which limit the movement of the jaw joint and muscles around it.
  • TMJ disorders can be caused by teeth grinding or clenching, excessive chewing, and stress.
  • "There are several ways that doctors treat TMJ disorders whether it's with physical therapy or even surgery.

Life Spine Announces Continued Success of the PROLIFT® Wedge Expandable Spacer System

Retrieved on: 
Tuesday, July 27, 2021

Life Spine, a leading medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the continued adoption and success of the PROLIFT Wedge Expandable Spacer System.

Key Points: 
  • Life Spine, a leading medical device company that designs, develops, manufactures and markets products for the surgical treatment of spinal disorders, announced today the continued adoption and success of the PROLIFT Wedge Expandable Spacer System.
  • The PROLIFT Wedge offers controlled lordotic expansion of up to 15, which was an ideal solution for this patient.
  • Suffering from severe disc degeneration, the collapsed discs required custom height expansion as well as sagittal alignment correction.
  • Through the use of expandable technology such as PROLIFT Wedge, the surgical goals were completed, said Dr. Adam Lewis of Flowood, MS.
    PROLIFT Wedge Expandable Spacer System features Osseo-Loc Surface Technology and is designed for Micro Invasive PLIF procedures.

Study shows Smith+Nephew's REGENETEN™ Bioinductive Implant sets new standard of recovery for partial-thickness rotator cuff tears

Retrieved on: 
Wednesday, July 21, 2021

Smith+Nephew's REGENETEN Bioinductive Implant is available in the US, Europe and other select countries worldwide.

Key Points: 
  • Smith+Nephew's REGENETEN Bioinductive Implant is available in the US, Europe and other select countries worldwide.
  • Treatment of partial-thickness rotator cuff tear repairs with a resorbable bioinductive bovine collagen implant: 1-year results from a prospective multi-center registry.
  • Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up.
  • Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up.

Study shows Smith+Nephew's REGENETEN◊ Bioinductive Implant sets new standard of recovery for partial-thickness rotator cuff tears

Retrieved on: 
Wednesday, July 21, 2021

Smith+Nephew's REGENETEN Bioinductive Implant is available in the US, Europe and other select countries worldwide.

Key Points: 
  • Smith+Nephew's REGENETEN Bioinductive Implant is available in the US, Europe and other select countries worldwide.
  • Treatment of partial-thickness rotator cuff tear repairs with a resorbable bioinductive bovine collagen implant: 1-year results from a prospective multi-center registry.
  • Evidence of healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a collagen implant: a 2-year MRI follow-up.
  • Healing of partial-thickness rotator cuff tears following arthroscopic augmentation with a highly porous collagen implant: a 5-year clinical and MRI follow-up.

Active Implants’ NUsurface® Meniscus Implant Provides Statistically Superior Pain Relief

Retrieved on: 
Thursday, July 15, 2021

Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the companys NUsurface Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy.

Key Points: 
  • Active Implants, LLC, a developer of orthopedic implant solutions for joint preservation, today announced two-year results of the MERCURY study, which showed that the companys NUsurface Meniscus Implant provides statistically superior pain relief beginning at six months compared to non-surgical therapy.
  • The medial meniscus replacement mimics the function of the natural meniscus and treats pain by redistributing loads transmitted across the knee joint.
  • Patients with replacement implants achieved superior results the second time; 70% of patients used one implant and 20% received a replacement implant.
  • The NUsurface Meniscus Implant is an investigational treatment for patients in the U.S. with persistent knee pain following medial meniscus surgery.

SI-BONE, Inc. Announces Centene Establishes Positive Coverage for MIS SI Joint Fusion including the Triangular iFuse Implant System

Retrieved on: 
Wednesday, July 14, 2021

SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.

Key Points: 
  • SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System.
  • This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.
  • The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis.
  • In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint.